Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease

Brain Research

Volumn 1646, Issue , 2016, Pages 354-365

  Hansen, Henrik H ^a   Fabricius, Katrine ^a   Barkholt, Pernille ^a   Mikkelsen, Jens D ^b   Jelsing, Jacob ^a   Pyke, Charles ^c   Knudsen, Lotte Bjerre ^c   Vrang, Niels ^a  

^a Gubra   (Denmark)

^b Rigshospitalet   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

6 Hydroxydopamine; Dopaminergic neuron; GLP 1 receptor agonist; Liraglutide; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

APOMORPHINE; DEXAMPHETAMINE; LIRAGLUTIDE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; ANTIPARKINSON AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; EXPERIMENTAL PARKINSONISM; MEDIAL FOREBRAIN BUNDLE; MESENCEPHALON; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; STEREOLOGY; AGONISTS; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; MALE; METABOLISM; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PATHOLOGY; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA;

ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; BODY WEIGHT; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DOPAMINERGIC NEURONS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; LIRAGLUTIDE; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84975699602     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2016.05.038     Document Type: Article

References (65)

1. A. Abuirmeileh, A. Harkavyi, N. Rampersaud, R. Lever, J.A. Tadross, S.R. Bloom, and P.S. Whitton Exendin-4 treatment enhances l-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat J. Pharm. Pharmacol. 64 2012 637 643
2. E. Alvarez, M.D. Martínez, I. Roncero, J.A. Chowen, B. García-Cuartero, J.D. Gispert, C. Sanz, P. Vázquez, A. Maldonado, J. de Cáceres, M. Desco, M.A. Pozo, and E. Blázquez The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem J. Neurochem. 92 2005 798 806
3. G. Ambrosi, M.T. Armentero, G. Levandis, P. Bramanti, G. Nappi, and F. Blandini Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease Brain Res. Bull. 82 2010 29 38
4. I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, J. Kahan, P. Ell, P. Whitton, R. Wyse, T. Isaacs, A. Lees, P. Limousin, and T. Foltynie Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease J. Park. Dis. 4 2014 337 344
5. C.J. Barnum, X. Chen, J. Chung, J. Chang, M. Williams, N. Grigoryan, R.J. Tesi, and M.G. Tansey Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro(R)1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats J. Park. Dis. 4 2014 349 360
6. F. Bassil, P.-O. Fernagut, E. Bezard, and W.G. Meissner Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog. Neurobiol. 118 2014 1 18
7. H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger Brain dopamine and the syndromes of Parkinson and Huntington clinical, morphological and neurochemical correlations J. Neurol. Sci. 20 1973 415 455
8. G. Bertilsson, C. Patrone, O. Zachrisson, A. Andersson, K. Dannaeus, J. Heidrich, J. Kortesmaa, A. Mercer, E. Nielsen, H. Rönnholm, and L. Wikström Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease J. Neurosci. Res. 86 2008 326 338
9. J. Blesa, and S. Przedborski Parkinson's disease: animal models and dopaminergic cell vulnerability Front. Neuroanat. 8 2014 155
10. S. Briyal, S. Shah, and A. Gulati Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia Neuroscience 281C 2014 269 281
11. L.S. Carman, F.H. Gage, and C.W. Shults Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior Brain Res. 553 1991 275 283
12. I. Creese, D.R. Burt, and S.H. Snyder Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity Science 197 1977 596 598
13. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909
14. B. DellaValle, C. Hempel, F.F. Johansen, and J.A.L. Kurtzhals GLP-1 improves neuropathology after murine cold lesion brain trauma Ann. Clin. Transl. Neurol. 1 2014 721 732
15. S.L. Dickson, R.H. Shirazi, C. Hansson, F. Bergquist, H. Nissbrandt, and K.P. Skibicka The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors J. Neurosci. 32 2012 4812 4820
16. E. Egecioglu, J.A. Engel, and E. Jerlhag The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice PloS One 8 2013 e77284
17. A.M. Espinosa-Oliva, R.M. de Pablos, M. Sarmiento, R.F. Villaran, A. Carrillo-Jimenez, M. Santiago, J.L. Venero, A.J. Herrera, J. Cano, and A. Machado Role of dopamine in the recruitment of immune cells to the nigro-striatal dopaminergic structures Neurotoxicology 41 2014 89 101
18. G. Fabbrini, J.M. Brotchie, F. Grandas, M. Nomoto, and C.G. Goetz Levodopa-induced dyskinesias Mov. Disord. 22 2007 1379 1389
19. G. Gu, B. Roland, K. Tomaselli, C.S. Dolman, C. Lowe, and J.S. Heilig Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication J. Comp. Neurol. 521 2013 2235 2261
20. H.J. Gundersen, P. Bagger, T.F. Bendtsen, S.M. Evans, L. Korbo, N. Marcussen, A. Møller, K. Nielsen, J.R. Nyengaard, and B. Pakkenberg The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis APMIS 96 1988 857 881
21. H.J. Gundersen, and E.B. Jensen The efficiency of systematic sampling in stereology and its prediction J. Microsc. 147 1987 229 263
22. R. Göke, P.J. Larsen, J.D. Mikkelsen, and S.P. Sheikh Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites Eur. J. Neurosci. 7 1995 2294 3000
23. J. Han, L. Sun, Y. Chu, Z. Li, D. Huang, X. Zhu, H. Qian, and W. Huang Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates J. Med. Chem. 56 2013 9955 9968
24. G. Hansen, J. Jelsing, and N. Vrang Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats Acta Pharmacol. Sin. 33 2012 194 200
25. H.H. Hansen, P. Barkholt, K. Fabricius, J. Jelsing, D. Terwel, C. Pyke, L.B. Knudsen, and N. Vrang The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy Brain Res. 1634 2016 158 170
26. H.H. Hansen, K. Fabricius, P. Barkholt, M.L. Niehoff, J.E. Morley, J. Jelsing, C. Pyke, L. Bjerre Knudsen, S.A. Farr, and N. Vrang The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of alzheimer's disease J. Alzheimers Dis. 46 2015 877 888
27. A. Harkavyi, A. Abuirmeileh, R. Lever, A.E. Kingsbury, C.S. Biggs, and P.S. Whitton Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease J. Neuroinflamm. 5 2008 1 9
28. M.R. Hayes, S.E. Kanoski, A.L. Alhadeff, and H.J. Grill Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats Obesity 19 2012 1342 1349
29. F. Hefti, E. Melamed, B.J. Sahakian, and R.J. Wurtman Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA Pharmacol. Biochem. Behav. 12 1980 185 188
30. K.M. Heppner, M. Kirigiti, A. Secher, S.J. Paulsen, R. Buckingham, C. Pyke, L.B. Knudsen, N. Vrang, and K.L. Grove Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain Endocrinology 1 2015 255 267
31. E. Hirsch, A.M. Graybiel, and Y.A. Agid Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease Nature 334 1988 345 348
32. C. Holscher Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases J. Endocrinol. 221 2014 T31 T41
33. X.T. Hu, S.R. Wachtel, M.P. Galloway, and F.J. White Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation J. Neurosci. 10 1990 2318 2329
34. J.L. Hudson, C.G. van Horne, I. Strömberg, S. Brock, J. Clayton, J. Masserano, B.J. Hoffer, and G.A. Gerhardt Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats Brain Res. 626 1993 167 174
35. H. Iderberg, V. Francardo, and E.Y. Pioli Animal models of l-DOPA-induced dyskinesia: an update on the current options Neuroscience 211 2012 13 27
36. J. Jelsing, N. Vrang, G. Hansen, K. Raun, M. Tang-Christensen, and L.B. Knudsen Liraglutide: short-lived effect on gastric emptying - long lasting effects on body weight Diabetes Obes. Metab. 14 2012 531 538
37. L.C. Johnston, X. Su, K. Maguire-Zeiss, K. Horovitz, I. Ankoudinova, D. Guschin, P. Hadaczek, H.J. Federoff, K. Bankiewicz, and J. Forsayeth Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease Mol. Ther. J. Am. Soc. Gene Ther. 16 2008 1392 1399
38. S.E. Kanoski, L.E. Rupprecht, S.M. Fortin, B.C. De Jonghe, and M.R. Hayes The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide Neuropharmacology 62 2012 1916 1927
39. A.J. Kastin, and V. Akerstrom Entry of exendin-4 into brain is rapid but may be limited at high doses Int. J. Obes. Relat. Metab. Disord. 27 2003 313 318
40. S. Kim, M. Moon, and S. Park Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease J. Endocrinol. 202 2009 431 439
41. P.J. Larsen, E.M. Wulff, C.F. Gotfredsen, C.L. Brand, J. Sturis, N. Vrang, L.B. Knudsen, and K. Lykkegaard Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats Diabetes Obes. Metab. 10 2008 301 311
42. A.J. Lees, J. Hardy, and T. Revesz Parkinson's disease Lancet 373 2009 2055 2066
43. Y. Li, M. Bader, I. Tamargo, V. Rubovitch, D. Tweedie, C.G. Pick, and N.H. Greig iraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice J. Neurochem. 2015
44. Y. Li, T. Perry, M.S. Kindy, B.K. Harvey, D. Tweedie, H.W. Holloway, K. Powers, H. Shen, J.M. Egan, K. Sambamurti, A. Brossi, D.K. Lahiri, M.P. Mattson, B.J. Hoffer, Y. Wang, and N.H. Greig GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism Proc. Natl. Acad. Sci. USA 106 2009 1285 1290
45. W. Liu, J. Jalewa, M. Sharma, G. Li, L. Li, and C. Holscher Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease Neuroscience 303 2015 42 50
46. S. Maia, N. Arlicot, E. Vierron, S. Bodard, J. Vergote, D. Guilloteau, and S. Chalon Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease Synapse 66 2012 573 583
47. I. Merchenthaler, M. Lane, and P. Shughrue Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system J. Comp. Neurol. 403 1999 261 280
48. E.G. Mietlicki-Baase, P.I. Ortinski, L.E. Rupprecht, D.R. Olivos, A.L. Alhadeff, R.C. Pierce, and M.R. Hayes The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors Am. J. Physiol. Endocrinol. Metab. 305 2013 E1367 E1374
49. C.W. Olanow, and A.H.V. Schapira Therapeutic prospects for Parkinson disease Ann. Neurol. 74 2013 337 347
50. C. Orskov, S.S. Poulsen, M. Møller, and J.J. Holst Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I Diabetes 45 1996 832 835
51. D. Parkes, C. Jodka, P. Smith, S. Nayak, L. Rinehart, R. Gingerich, K. Chen, and A. Young Pharmacokinetic actions of exendin-4 in the rat: Comparison With glucagon-like peptide-1 Drug Dev. Res. 53 2001 260 267
52. V. Parthsarathy, and C. Hölscher Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model PloSOne 8 2013 e58784
53. G. Paxinos, and W. Watson The rat brain in stereotaxic coordinates 1987 Academic Press Ltd. London, UK London EDI-3rd
54. M. Sadeghian, L. Marinova-Mutafchieva, L. Broom, J.B. Davis, D. Virley, A.D. Medhurst, and D.T. Dexter Full and partial peroxisome proliferation-activated receptor-gamma agonists, but not delta agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression J. Neuroimmunol. 246 2012 69 77
55. J.A. Santiago, and J.A. Potashkin Shared dysregulated pathways lead to Parkinson's disease and diabetes Trends Mol. Med. 19 2013 176 186
56. R.K. Schwarting, and J.P. Huston The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments Prog. Neurobiol. 50 1996 275 331
57. A. Secher, J. Jelsing, A.F. Baquero, J. Hecksher-Sørensen, M.A. Cowley, L.S. Dalbøge, G. Hansen, K.L. Grove, C. Pyke, K. Raun, L. Schäffer, M. Tang-Christensen, S. Verma, B.M. Witgen, N. Vrang, and L.B. Knudsen The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss J. Clin. Investig. 124 2014 4473 4488
58. S. Sisley, R. Gutierrez-Aguilar, M. Scott, D.A. D'Alessio, D.A. Sandoval, and R.J. Seeley Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect J. Clin. Investig. 124 2014 2456 2463
59. A.K. Stark, and B. Pakkenberg Histological changes of the dopaminergic nigrostriatal system in aging Cell Tissue Res. 318 2004 81 92
60. J. Sturis, C.F. Gotfredsen, J. Rømer, B. Rolin, U. Ribel, C.L. Brand, M. Wilken, K. Wassermann, C.F. Deacon, R.D. Carr, and L.B. Knudsen GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics Br. J. Pharmacol. 140 2003 123 132
61. K. Talbot Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs Neurodegener. Dis. Manag. 4 2014 31 40
62. T.A. Wadden, P. Hollander, S. Klein, K. Niswender, V. Woo, P.M. Hale, L. Aronne, and N.N. Investigators Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study Int. J. Obes. 37 2013 1443 1451
63. S. Walsh, D.P. Finn, and E. Dowd Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat Neuroscience 175 2011 251 261
64. M.J. West Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias Trends Neurosci. 22 1999 51 61
65. H. Xiong, C. Zheng, J. Wang, J. Song, G. Zhao, H. Shen, and Y. Deng The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice J. Alzheimers Dis. 37 2013 623 635